Salvage radiation dose: decision-making under uncertainty

A large, well-done, confirmed, randomized clinical trial (RCT) is the only evidence that proves that one therapy is better than other. According to current consensus, this is deemed “Level 1a” evidence. But this high level of evidence is seldom available. … READ MORE …

Low-dose abiraterone with food proves its worth in small Phase II trial

We have known for some time that taking abiraterone acetate (Zytiga) with food (as opposed to on an empty stomach) might well allow patients to be able to take significantly lower doses of this product and gain the same clinical benefit as is currently known to be beneficial from taking 1,000 mg/day when fasting. … READ MORE …

FDA approves lower dose of cabazitaxel in treatment of mCRPC

Yesterday, in line with previously reported data, the US Food and Drug Administration (FDA) approved the used of a 20 mg/ml dose of cabazitaxel (Jevtana) in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

SBRT dose escalation

Is there an optimum treatment dose for sterotactic body radiation therapy (SBRT)? … READ MORE …

Dose escalation for salvage radiation therapy

In the late 1990s and early 2000s, the advent of more accurate linear accelerators (LINACs) and image-guidance technology for delivering therapeutic X-rays to the prostate in the treatment of prostate cancer changed the dose that could be safely given. … READ MORE …

How NOT to give salvage radiation after primary radiation failure

Recently, we commented on a couple of small studies where radiation re-treatment was used effectively and with acceptable toxicity. … READ MORE …

Safety limits of SBRT dose escalation

In a recent commentary, we saw that the lack of a standard of care for stereotactic body radiation therapy (SBRT) dose escalation may put patients at risk when dose limits are pushed beyond what is customarily considered effective and safe. … READ MORE …